Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
暂无分享,去创建一个
B. Brundage | H. Ghofrani | R. Barst | G. Simonneau | R. Oudiz | N. Galiè | A. Beardsworth | F. Botros | M. Chan | G. Simonneau | R. Barst | H. Ghofrani
[1] M. Humbert,et al. Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.
[2] T. Fleming,et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.
[3] G. Simonneau,et al. Perspective on the optimal endpoints for pulmonary arterial hypertension trials , 2010, Current opinion in pulmonary medicine.
[4] H. Ghofrani,et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[5] G. Simonneau,et al. The use of combination therapy in pulmonary arterial hypertension: new developments , 2009, European Respiratory Review.
[6] P. Thistlethwaite,et al. Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[7] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[8] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.
[9] M. Humbert,et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.
[10] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[11] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.